Drug Search Results
More Filters [+]

NIM-1324

Alternative Names: NIM-1324, NIM1324, NIM 1324, labp-104, labp 104, labp104
Latest Update: 2024-10-07
Latest Update Note: News Article

Product Description

A novel, oral, systemically delivered LANCL2 agonist,for the treatment of rheumatoid arthritis (Sourced from: https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-announces-fda-clearance-its-ind-labp-104-0)

Mechanisms of Action: LANCL2 Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: NImmune Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NIM-1324

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Lupus Erythematosus, Systemic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LABP-104-1a

P1

Completed

Lupus Erythematosus, Systemic

2022-04-28

Recent News Events